Inhibrx Biosciences (INBX) EBITDA Margin (2023 - 2025)

Inhibrx Biosciences (INBX) has 3 years of EBITDA Margin data on file, last reported at 2106.85% in Q2 2025.

• On a quarterly basis, EBITDA Margin rose 15879115.0% year-over-year to 2106.85% in Q2 2025; TTM through Dec 2025 was 9644.64%, a 842777.0% increase from a year earlier, with the FY2025 full-year figure at 10386.54%, up 15533746.0% from the prior year.
• EBITDA Margin for Q2 2025 stood at 2106.85%, up from 49928.0% in the prior quarter.
• Over the last five years, EBITDA Margin for INBX reached as high as 2106.85% in Q2 2025 and fell as low as 160898.0% in Q2 2024.
• Historically, EBITDA Margin has averaged 65773.81% across 3 years, with a median of 44219.04% in 2023.
• Across the five-year window, EBITDA Margin slumped 4452476 bps in 2024 and jumped 15879115 bps in 2025, its largest moves.
• Year by year, EBITDA Margin stood at 5403.24% in 2023, then tumbled by 824 bps to 49928.0% in 2024, then soared by 96 bps to 2106.85% in 2025.
• Per Business Quant data, the three most recent EBITDA Margin figures were 2106.85% in Q2 2025, 49928.0% in Q4 2024, and 160898.0% in Q2 2024.